Pulike Biological Engineering, Inc. Class A

Pulike Biological Engineering, Inc. Class A

SSSE:603566
9.05
CNY
-0.04
(-0.44%)
0.25EPS
32.54P/E
3.54BMarket Cap
Apr 23Next Earn
Pulike Biological Engineering, Inc. Class A
SSE:603566
(Shanghai Stock Exchange)

Recent

price

9.05

P/E

ratio

32.54

div

yld

6.66%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.22
1.72
1.74
1.97
1.98
1.65
1.83
1.67
1.88
2.06
2.94
3.51
3.81
3.59
3.03
3.18
2.94
Revenue per Share
0.35
0.48
0.54
0.68
0.58
0.49
0.59
0.36
0.42
0.34
0.72
0.78
0.52
0.5
0.27
0.54
0.31
Basic EPS, GAAP
- -
- -
0.26
0.28
0.36
0.2
0.56
0.26
0.23
0.17
0.27
-0.34
-0.4
-0.06
0.43
0.82
- -
Free Cash Flow per Basic Share
0.34
0.61
0.02
- -
0.25
0.17
0.15
0.2
0.2
0.3
0.2
0.5
0.2
0.64
0.4
0.6
0.6
Dividend per Share
0.82
1.3
1.84
2.51
2.85
4.18
4.57
4.85
5.08
5.16
5.32
5.6
7.95
7.72
7.59
7.53
7.36
Book Value per Share
0.63
0.98
1.32
2.01
2.37
3.46
3.91
4.2
4.4
4.42
4.57
4.69
7.08
6.86
6.73
6.57
6.41
Tangible Book Value per Share
240
240
239
240
240
289
319
317
323
321
316
313
323
349
344
343
341
Basic Weighted Avg Shares
292
413
418
472
476
478
583
530
608
663
929
1,099
1,230
1,253
1,043
1,090
1,005
Sales/Revenue/Turnover
32.57
33.23
34.91
36.18
33.29
30.53
28.13
16.55
20.23
13.65
23.28
24.68
17.32
17.09
10.62
17.45
10.28
Operating Margin (%)
- -
- -
23
25
31
32
34
37
42
50
51
59
75
93
122
122
- -
Depreciation Expense
84
115
129
163
140
142
188
114
136
109
228
244
168
175
93
185
107
Net Income, GAAP
18.85
15.92
14.46
15.2
16.03
15.9
14.89
14.36
11.49
6.78
12.41
14.09
5.57
10.33
6.03
10.78
11.74
Effective Tax Rate (%)
28.73
27.96
30.95
34.5
29.48
29.64
32.24
21.55
22.3
16.47
24.53
22.22
13.64
13.93
8.9
16.97
10.69
Profit Margin (%)
31
90
137
189
266
824
901
945
765
698
590
388
1,127
901
834
942
1,032
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
- -
20
19
LT Debt
196
311
440
603
684
1,337
1,481
1,569
1,645
1,658
1,710
1,800
2,804
2,724
2,626
2,737
2,657
Total Equity
28.78
32.1
26.18
26.02
20.56
12.87
11.06
6.06
7.57
6.09
12.97
14.1
7.31
6.35
3.51
6.96
3.22
Return on Invested Capital (%)
35.52
36.71
28.98
29.8
21.61
13.62
13.08
7.28
8.46
6.65
13.53
13.91
7.3
6.33
3.47
6.86
4.95
Return on Capital (%)
37.75
45.5
34.38
31.21
21.8
14.03
13.34
7.49
8.44
6.61
13.53
13.91
7.29
6.31
3.47
7.07
4.17
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
7
7
7
LT Borrowings
19
18
18
LT Finance Leases
2
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
346
346
346
Market Capitalization
4,277
3,388
3,544

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,406
1,404
1,412
Cash, Cash Equivalents & STI
754
735
801
Accounts Receivable, Net
390
392
389
Inventories
230
241
189
Total Current Liabilities
368
406
379
Payables & Accruals
- -
- -
- -
ST Debt
7
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.43%
11.76%
4.22%
Free Cash Flow
-79.21%
-191.8%
90.42%
Net Income, GAAP
13.36%
6.49%
99.33%
Sales/Revenue/Turnover
9.66%
3.98%
4.54%
Total Cash Common Dividend
- -
70.61%
48.83%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
248
279
281
1,043
2025
279
281
- -
267
1,090
2026
249
242
247
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.14
0.09
-0.04
0.27
2025
0.16
0.19
- -
0.08
0.54
2026
0.12
0.11
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
0.2
0.6
2026
- -
0.4
- -
- -
- -
Business
Pulike Biological Engineering, Inc. (603566.SS) engages primarily in the research, development, production and sale of veterinary biological products and drugs; its core offerings encompass vaccines, antibodies and medicines for swine and poultry, alongside disinfectants, chemical preparations and traditional Chinese veterinary medicines; the company further provides vaccines and pharmaceuticals for ruminants including cattle and sheep, as well as for pets, with specific products such as porcine circovirus vaccines, mycoplasma vaccines, swine foot-and-mouth disease vaccines, new-branch-stream trivalent inactivated vaccines, new-branch-reduce-stream quadrivalent inactivated vaccines, chicken infectious bursal disease refined egg yolk antibodies and duck viral hepatitis refined egg yolk antibodies. Founded in 1995 and headquartered in Luoyang, Henan province, China, Pulike Biological Engineering, Inc. operates as a state-level high-tech enterprise with comprehensive strength ranking at the industry forefront; it maintains seven subsidiaries focused on vaccines, chemicals and pets, plus two shareholding companies in vaccines and testing, serving primarily the domestic Chinese animal health market while pursuing international expansion through the Belt and Road initiative. In recent developments, the company anticipates receiving CNY 900 million in funding from a group of investors, bolstering its research and development efforts where it invests over 10% of revenues—equivalent to $178 million in 2022—across more than 150 products produced via six GMP facilities and 50 product lines employing over 1,700 staff including 200 in R&D.